Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genix Pharmaceuticals Corporation (GENPF)
Vancouver, BC, CA
Genix Pharmaceuticals Corporation, established in 1993 and headquartered in Vancouver, Canada, is actively involved in the creation, production, licensing, and distribution of various life science products. The company's primary focus in the Canadian market is on nutraceuticals and pharmaceuticals. Their product pipeline features several key developments: Flu-X: An herbal treatment available as an oral solution or spray, targeting viral infections, influenza, and coronaviruses responsible for common colds. Renochlor: A nutritional supplement formulated to support the revitalization and maintenance of kidney health and function. Sucanon: An insulin sensitizer designed to reduce blood sugar by improving the sensitivity of muscle, fat, and liver cells to insulin. Beyond these, Genix Pharmaceuticals also offers a wide range of other nutraceuticals and pharmaceutical items. This selection includes supplements such as bee propolis capsules, liquid calcium softgels, seal oil softgels, marine lipid softgels, lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, alongside ophthalmic products like eye ointments and drops. The company operated under the name Alta Natural Herbs & Supplements Ltd. until it adopted its current identity, Genix Pharmaceuticals Corporation, in June 2019.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -53.00% | -53.00% | -64.75% | -60.39% | -91.52% | -90.41% | -90.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-100.0%
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-366.7% Q2'26: +233.3% (vs Q2'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q2'26: +13.4% (vs Q2'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.5% Q2'26: +3.4% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-4.60× Q2'26: -7.25× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Raylen Tamayo | Chief Financial Officer | 26.3K | female |
| Wayne Kent Lee | Chief Financial Officer | 26.3K | male |
| Kevin James Bottomley | Director of Corporate Development & Independent Director | 723 | male |
| Mahmoud S. Aziz | Chairman of the Board & President | — | male |
| Sina Salehi Pirooz | Chief Executive Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GENPF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
